Pricing Log in Create free account
Friday 6 November 2026 Export LAB’s income statement to Excel — free account

Standard BioTools Inc.

LAB Healthcare Medical Devices

Standard BioTools Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.3 million, down 6.24% from fiscal 2024.

Revenue
−0.85%
EPS
+138.1%
Free cash flow
+73.3%
Total debt
+0.33%

Quarter to September 2026, against a year earlier

0.62 0.00 0.00%
Market cap
$245.7M
P/E
1.8×
Fwd P/E
−6.1×
Dividend yield
—
F-score
4/9
Altman Z
−0.82
Beneish M
−2.93
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.55
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 1 — — — — — — — — — — 1
Sell — — — — — — — — — — — —
Insider Ownership 3.80%

Capital & Financial Ratios $m

Size
Market Cap 245.72
Revenue ttm 84.43
Net income ttm 133.08
Free cash flow ttm (65.65)
Net debt Q (460.81)
Valuation
P/E 1.80
Forward P/E (6.10) (negative: loss-making)
Price / sales 2.89
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.44
Financial health
Current ratio Q 9.75 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (1,540.25)
Growth
Revenue growth Q −0.85% (below 0%: shrinking)
Operating income growth Q +39.98% (above 0%: growing)
EPS, this year +33.33% (at or above 15%: strong)
EPS, next year A −60.00% (below 0%: weak)
Revenue, next year A −3.32% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +2.27%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −2.5×, against a ten-year median of 2.8×; over the ten years it ranged from −2.6× in 2026 to 6.7× in 2019.
P/S against its own 10 years 58.27%
10-year low 10-year high
P/B against its own 10 years 0.44%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 115 293 188 461
Receivables 20 15 13 13
Inventory 21 21 20 18
Other — 43 228 —
158 376 454 497
2023 2024 2025 Q'26
Payables 9 5 5 3
ST’ Debt 5 — — —
Other — 21 26 —
109 66 108 51

Compound Annual Growth %

10y 5y 3y
Sales (2.92%) (9.19%) (4.49%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 13.96% 25.00% 22.68%

Earnings Trends EPS, adjusted, against the consensus

Q1 FY26 Estimate −0.02 Actual −0.02

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY25 −0.04 −0.04 Met by 0.00
Q2 FY25 −0.04 −0.04 Met by 0.00
Q4 FY25 −0.03 0.06 Beat by 0.09
Q1 FY26 −0.02 −0.02 Met by 0.00

EPS $

Mar Jun Sep Dec Year
’26 0.33 (0.07) 0.03 — —
’25 (0.07) (0.09) (0.09) 0.05 (0.20)
’24 (0.27) (0.12) (0.07) (0.09) (0.52)
’23 (0.21) (0.22) (0.27) (0.25) (0.94)
’22 (0.99) (0.82) (0.37) (0.26) (2.43)
’21 (0.25) (0.23) (0.18) (0.12) (0.78)
’20 (0.23) (0.18) (0.08) (0.24) (0.74)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 21 20 19 — —
’25 20 22 20 24 85
’24 46 22 22 1 91
’23 25 28 25 28 106
’22 27 19 26 27 98
’21 33 31 29 38 131
’20 28 26 40 45 138
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (47) (10) (6) — —
’25 (30) (21) (22) (1) (74)
’24 (62) (39) (28) (14) (143)
’23 (8) (9) (11) (14) (43)
’22 (16) (30) (25) (19) (89)
’21 (13) (15) (9) (7) (44)
’20 (4) (3) (5) (4) (15)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (47) (11) (6) — —
’25 (35) (23) (23) (2) (83)
’24 (63) (41) (30) (17) (152)
’23 (9) (10) (12) (14) (46)
’22 (16) (31) (26) (20) (93)
’21 (20) (19) (11) (7) (57)
’20 (5) (3) (5) (14) (28)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 104 102 113 117 138 131 98 106 91 85 84 (2.2%) 83 82 86 +0.1%
Gross margin, % 55.95 50.99 54.57 54.83 60.32 53.13 37.83 47.44 49.32 49.86 52.18 (6.1) pt
EBT (80) (64) (61) (67) (54) (64) (193) (74) (90) (97) (73) +2.1%
EBT margin, % (76.76) (62.59) (54.37) (56.89) (39.16) (48.75) (196.97) (69.78) (99.33) (113.33) (86.50) (36.6) pt
Net income (76) (61) (59) (65) (53) (59) (190) (75) (139) (75) 133 (0.2%)
Per share, $
Per share, $ Revenue 3.60 3.09 2.85 1.76 1.92 1.72 1.25 1.34 0.26 0.22 0.21 (26.6%)
Earnings (2.62) (1.84) (1.49) (0.97) (0.74) (0.78) (2.43) (0.94) (0.52) (0.20) 0.34 (24.9%)
Cash flow (1.35) (0.73) (0.64) (0.53) (0.21) (0.58) (1.14) (0.55) (0.41) (0.19) (0.16) (19.3%)
Capex (0.17) (0.05) (0.01) (0.04) (0.18) (0.17) (0.05) (0.04) (0.02) (0.02) 0.00 (20.6%)
Free cash flow (1.52) (0.78) (0.64) (0.57) (0.39) (0.76) (1.19) (0.58) (0.43) (0.22) (0.17) (19.5%)
Book value 1.84 0.94 1.82 2.30 1.93 1.25 2.93 2.06 1.34 1.11 1.41 (5.4%)
Shares, m 29 33 40 67 72 76 78 79 353 382 389 +33.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.80 0.0
P/S 2.11 2.02 3.03 1.98 3.13 2.28 1.04 1.65 6.79 5.72 2.89 3.0
P/B 4.14 6.64 4.74 1.51 3.11 3.14 0.00 0.00 1.31 1.15 0.44 2.6
EV/Sales 3.41 3.31 3.70 1.96 3.05 2.60 0.01 0.66 3.63 3.59 (2.51) 2.6
EV/FCF (6.99) (10.46) (13.01) (5.17) (12.12) (5.31) (0.01) (1.32) (2.09) (3.43) 2.93 (6.0)
Cash, $m
Cash, $m Operating cash flow (39) (24) (25) (35) (15) (44) (89) (43) (143) (74) (64) +7.4%
Capex (5) (2) 0 (3) (13) (13) (4) (3) (8) (8) (1) +5.6%
Free cash flow (44) (26) (26) (38) (28) (57) (93) (46) (152) (83) (66) +7.2%
Balance, $m
Balance, $m Working capital 67 61 90 63 63 22 165 49 310 346 446 +20.0%
Net debt 136 132 77 (3) (11) 43 (101) (106) (293) (187) (461) n/m
Shareholders’ equity 53 31 72 154 139 95 230 163 472 424 556 +25.9%
Returns, %
Returns, % ROA (22.47) (20.39) (19.97) (22.79) (17.99) (19.75) (57.13) (20.93) (39.53) (12.69) 22.65 +9.8 pt
ROIC (24.23) (22.37) (20.23) (21.51) (24.97) (30.73) (56.35) (83.57) (44.48) (29.07) (54.18) (4.8) pt
ROE (90.39) (143.84) (114.53) (57.41) (36.23) (50.71) (2,895.83) 65.05 (114.25) (16.72) 27.86 +73.7 pt
People
People Employees 589 505 535 566 627 615 523 539 818 389 — (4.5%)
Revenue/emp, $m 0.18 0.20 0.21 0.21 0.22 0.21 0.19 0.20 0.11 0.22 — +2.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Standard BioTools Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TMCI Treace Medical Concepts, Inc. $271.9M — (loss-making) — (loss-making) −4.24% (below 0%: shrinking) n/m +11.74% (above 0%: growing) 78.47% (32.96%) Compare
INFU InfuSystems Holdings, Inc. $270.1M 32.0× 33.0× +2.59% (above 0%: growing) +33.33% (above 0%: growing) −66.54% (below 0%: shrinking) 57.98% 11.24% Compare
QSI Quantum-Si Incorporated $256.1M — (loss-making) — (loss-making) −61.59% (below 0%: shrinking) n/m +37.48% (above 0%: growing) 34.91% (11,215.09%) Compare
PROF Profound Medical $251.3M — (loss-making) — (loss-making) +85.86% (above 0%: growing) n/m +47.93% (above 0%: growing) 78.13% (79.56%) Compare
LAB Standard BioTools Inc. $245.7M 1.8× — (loss-making) −0.85% (below 0%: shrinking) n/m +73.32% (above 0%: growing) 55.86% (101.98%)
ELMD Electromed, Inc. $221.8M 19.4× 18.6× +11.64% (above 0%: growing) +57.69% (above 0%: growing) −25.15% (below 0%: shrinking) 78.71% 19.70% Compare
TLSI TriSalus Life Sciences, Inc. $217.4M — (loss-making) — (loss-making) +1.73% (above 0%: growing) n/m −41.29% (below 0%: shrinking) 86.78% (86.03%) Compare
RXST RxSight, Inc. $190.4M — (loss-making) — (loss-making) −18.97% (below 0%: shrinking) n/m +2,591.06% (above 0%: growing) 73.62% (75.32%) Compare
STIM Neuronetics, Inc. $185.2M — (loss-making) — (loss-making) +12.51% (above 0%: growing) n/m +237.71% (above 0%: growing) 52.17% 1.29% Compare
Median of peers $236.6M — — +2.16% — +24.61% 75.88% (54.14%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Directors and executive officers, together 26.81%
Eli Casdin 23.88%
Entities affiliated with Casdin Capital, LLC 22.75%
Entities affiliated with Viking Global Investors LP 15.03%
BlackRock, Inc. 5.75%
Entities affiliated with MAK Capital Fund LP 5.12%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Standard BioTools Inc. (LAB) Latest News

3 Nov

Impact 3 · · GlobeNewswire

5 Oct

Impact 4 · · GlobeNewswire

30 Sep

Impact 4 · · GlobeNewswire

5 Aug

Impact 3 ·

28 Jul

Impact 4 ·
Impact 4 ·

20 Jul

Impact 3 ·

9 Jun

Impact 4 · · biopharmadive.com

8 Jun

Impact 4 · · GlobeNewswire

5 May

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

24 Feb

Impact 4 · · Associated Press Finance
Impact 4 · · GlobeNewswire

10 Feb

Impact 3 · · GlobeNewswire

30 Jan

Impact 4 · · GlobeNewswire

24 Jan

Impact 3 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

8 Jan

Impact 4 · · GlobeNewswire

28 Dec

Impact 4 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

1 Dec

Impact 3 · · Simply Wall St.

19 Nov

Impact 4 · · Business Wire

10 Nov

Impact 4 · · PR Newswire

5 Nov

Impact 3 · · Simply Wall St.

4 Nov

Impact 3 · · Associated Press Finance
Impact 3 · · GlobeNewswire

21 Oct

Impact 3 · · GlobeNewswire

3 Sep

Impact 4 · · PR Newswire

13 Aug

Impact 3 · · Simply Wall St.

11 Aug

Impact 3 ·
Impact 3 ·
Impact 3 ·
stockrow.com/LAB · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com